|Awarded On||August 17, 2016|
|Title||Acute Myeloid Leukemia in the Immunosuppressed Microenvironment|
|Award Mechanism||Multi-Investigator Research Awards (Version 2)|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Michael Andreeff|
Acute myeloid leukemias (AML) are malignant diseases of the bone marrow that rapidly lead to death if left untreated. These leukemias originate in very primitive stem cells in the bone marrow and prevent the development of normal blood cells, including infection-fighting white cells, oxygen-carrying red cells and platelets that prevent bleeding. Prevention is not currently possible and unlike solid tumors the disease is systemic at diagnosis preventing “early diagnosis.” Importantly the incidence is increasing with age, which explains the increase in patients in an aging population. Since 1976 the treatment of AML has consisted of the combined usage of two drugs (ARA-C and DNR) which puts a ...